Google
KYTX — KYVERNA THERAPEUTICS, INC. COMMON STOCK (Healthcare >> Biotechnology)
KYTX FAQ
What is KYTX's ROE?
KYVERNA THERAPEUTICS, INC. COMMON STOCK reports a Return on Equity (ROE) of -79.97%.
What is KYTX's dividend yield?
KYVERNA THERAPEUTICS, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is KYTX's Deepscope Quality Score?
Deepscope rates KYTX's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy KYTX?
Deepscope's AI Timing Score for KYTX is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does KYTX belong to?
KYVERNA THERAPEUTICS, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 7.85
Price
-0.19
(-2.42%)
Day Change
|
|
|---|
KYTX, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 7.85 |
| PBV / Sector |
2.32 / 4.71
|
| Earning Per Share | -2.70 |
| PE / Sector |
N/A / 17.58
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
7.64 M
|
| Average 1W Daily Value |
4.82 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
47% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-06-10 09:43:59 |
| Symbol | KYTX |
| Name | KYVERNA THERAPEUTICS, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 60.80 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 454.14 / 8,889.42 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 5980 Horton Street, Emeryville, CA, United States, 94608
Phone: 510 925 2492
Website: https://kyvernatx.com
Employees: 130
Sector: Healthcare >> Biotechnology
Description: Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
